Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1984 1
1985 2
1986 2
1987 3
1988 4
1989 7
1990 4
1991 3
1992 3
1994 5
1995 1
1996 7
1997 1
1998 1
1999 3
2000 3
2001 4
2003 4
2004 2
2005 2
2006 6
2007 5
2008 1
2009 3
2010 2
2012 4
2013 3
2015 1
2016 2
2017 3
2018 2
2020 3
2021 1
2022 3
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

91 results
Results by year
Filters applied: . Clear all
Page 1
Liposomal doxorubicin attenuates cardiotoxicity via induction of interferon-related DNA damage resistance.
Gyöngyösi M, Lukovic D, Zlabinger K, Spannbauer A, Gugerell A, Pavo N, Traxler D, Pils D, Maurer G, Jakab A, Riesenhuber M, Pircher A, Winkler J, Bergler-Klein J. Gyöngyösi M, et al. Cardiovasc Res. 2020 Apr 1;116(5):970-982. doi: 10.1093/cvr/cvz192. Cardiovasc Res. 2020. PMID: 31346605 Free article.
METHODS AND RESULTS: We treated domestic pigs with either DOX, epirubicin (EPI), or liposomal DOX and compared the cardiac, laboratory, and haemodynamic effects with saline-treated animals. ...Cardiac magnetic resonance imaging with gadolinium late enhancement and transtho …
METHODS AND RESULTS: We treated domestic pigs with either DOX, epirubicin (EPI), or liposomal DOX and compared the cardiac, laborator …
Changes in ischemia-modified albumin in myocardial toxicity induced by anthracycline and docetaxel chemotherapy.
Luan XD, Zhao KH, Hou H, Gai YH, Wang QT, Mu Q, Wan Y. Luan XD, et al. Medicine (Baltimore). 2017 Aug;96(32):e7681. doi: 10.1097/MD.0000000000007681. Medicine (Baltimore). 2017. PMID: 28796051 Free PMC article.
This study aims to evaluate differences in myocardial toxicity induced by different chemotherapy regimens. Patients were divided into 2 groups: epirubicin (EPI) combined with cyclophosphamide (EC) group and docetaxel combined with cyclophosphamide (TC) group. …
This study aims to evaluate differences in myocardial toxicity induced by different chemotherapy regimens. Patients were divid …
Pharmacokinetic and myocardial enzyme profiles of two administration routes of epirubicin in breast cancer patients.
Yang RX, Ren HX, Zhuang L, Gao CL, Dong C, Luo CX, Wang XN, Feng EF, He JC. Yang RX, et al. Arzneimittelforschung. 2012 Dec;62(12):677-81. doi: 10.1055/s-0032-1331166. Epub 2012 Nov 30. Arzneimittelforschung. 2012. PMID: 23203544 Clinical Trial.
Plasma concentration of epirubicin at different time points was determined using LC-MS/MS. The levels of myocardial enzymes before and after chemotherapy were compared. ...The higher peak plasma concentration observed following epirubicin administration by ID …
Plasma concentration of epirubicin at different time points was determined using LC-MS/MS. The levels of myocardial enzymes be …
Anthracycline-induced cardiomyopathy.
Keefe DL. Keefe DL. Semin Oncol. 2001 Aug;28(4 Suppl 12):2-7. Semin Oncol. 2001. PMID: 11552224 Review.
The highly active chemotherapeutic agents doxorubicin, duanorubicin, idarubicin, epirubicin, and mitoxantrone are also associated with acute, largely reversible cardiotoxic effects and a dose-related cardiomyopathy. ...Monitoring by assessment of left ventricular function …
The highly active chemotherapeutic agents doxorubicin, duanorubicin, idarubicin, epirubicin, and mitoxantrone are also associated wit …
Comparative cardiac toxicity of anthracyclines in vitro and in vivo in the mouse.
Toldo S, Goehe RW, Lotrionte M, Mezzaroma E, Sumner ET, Biondi-Zoccai GG, Seropian IM, Van Tassell BW, Loperfido F, Palazzoni G, Voelkel NF, Abbate A, Gewirtz DA. Toldo S, et al. PLoS One. 2013;8(3):e58421. doi: 10.1371/journal.pone.0058421. Epub 2013 Mar 14. PLoS One. 2013. PMID: 23516478 Free PMC article.
PURPOSE: The antineoplastic efficacy of anthracyclines is limited by their cardiac toxicity. In this study, we evaluated the toxicity of doxorubicin, non-pegylated liposomal-delivered doxorubicin, and epirubicin in HL-1 adult cardiomyocytes in culture as well …
PURPOSE: The antineoplastic efficacy of anthracyclines is limited by their cardiac toxicity. In this study, we evaluated the toxic …
Surface-modified Epirubicin-HCl liposomes and its in vitro assessment in breast cancer cell-line: MCF-7.
Gandhi R, Khatri N, Baradia D, Vhora I, Misra A. Gandhi R, et al. Drug Deliv. 2016 May;23(4):1152-62. doi: 10.3109/10717544.2014.999960. Epub 2015 Jan 14. Drug Deliv. 2016. PMID: 25586675
BACKGROUND: Epirubicin-HCl is highly efficient for breast cancer management at a concentration of 60-90 mg/m(2). However, its application is limited due to cumulative dose-dependent cardio-toxicity. PURPOSE: The main aim of this study was to formulate breast cancer- …
BACKGROUND: Epirubicin-HCl is highly efficient for breast cancer management at a concentration of 60-90 mg/m(2). However, its applica …
[Anthracycline-induced cardiotoxicity].
Petit T. Petit T. Bull Cancer. 2004 Nov;91 Suppl 3:159-65. Bull Cancer. 2004. PMID: 15899623 Free article. Review. French.
Generation of free radicals appears to be the main cause of myocardial damage in late-onset cardiotoxicity. Anthracycline toxicity is exacerbated in pediatric and elderly population. ...Endomyocardial biopsy is the only specific test for early diagnosis of anthracyc …
Generation of free radicals appears to be the main cause of myocardial damage in late-onset cardiotoxicity. Anthracycline toxicity …
The relative toxicity of intravenous and intraperitoneal doses of epirubicin.
Yeung TK, Simmonds RH, Hopewell JW. Yeung TK, et al. Cancer Chemother Pharmacol. 1989;24(4):211-8. doi: 10.1007/BF00257620. Cancer Chemother Pharmacol. 1989. PMID: 2752500
The toxicity of single doses of the anthracycline epirubicin was compared in the rat after either the intravenous (i.v.; 2-6 mg/kg) or intraperitoneal (i.p.; 4-8 mg/kg) administration of the drug. ...There was no qualitative difference in the histological lesions in …
The toxicity of single doses of the anthracycline epirubicin was compared in the rat after either the intravenous (i.v.; 2-6 m …
[Epirubicin (4'-epi-adriamycin].
Tsukagoshi S. Tsukagoshi S. Gan To Kagaku Ryoho. 1990 Jan;17(1):151-9. Gan To Kagaku Ryoho. 1990. PMID: 2404456 Review. Japanese.
In a comparative study of chronic cardiotoxicity, it was noted that epirubicin produced less damage to the myocardium than doxorubicin when every morphological change was examined as an indicator. Electrocardiographic and histopathological findings also disclosed th …
In a comparative study of chronic cardiotoxicity, it was noted that epirubicin produced less damage to the myocardium than dox …
Doxorubicinolone formation and efflux: a salvage pathway against epirubicin accumulation in human heart.
Salvatorelli E, Menna P, Lusini M, Covino E, Minotti G. Salvatorelli E, et al. J Pharmacol Exp Ther. 2009 Apr;329(1):175-84. doi: 10.1124/jpet.108.149260. Epub 2009 Jan 14. J Pharmacol Exp Ther. 2009. PMID: 19144686
Cardiomyopathy may occur independent of toxic metabolites if a given anthracycline tends to accumulate in the heart; therefore, we characterized whether epirubicin showed an unusual accumulation in human myocardial strips incubated in plasma. Epirubicin …
Cardiomyopathy may occur independent of toxic metabolites if a given anthracycline tends to accumulate in the heart; therefore, we ch …
91 results